Fedotozine

Fedotozine
Clinical data
Routes of
administration		Oral
ATC code
  • None
Legal status
Legal status
  • In general: non-regulated
Identifiers
  • (2R)-N,N-dimethyl-2-phenyl-1-[(3,4,5-trimethoxybenzyl)oxy]-2-butanamine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H31NO4
Molar mass373.493 g·mol−1
3D model (JSmol)
  • O(c1cc(cc(OC)c1OC)COC[C@@](c2ccccc2)(N(C)C)CC)C
  • InChI=1S/C22H31NO4/c1-7-22(23(2)3,18-11-9-8-10-12-18)16-27-15-17-13-19(24-4)21(26-6)20(14-17)25-5/h8-14H,7,15-16H2,1-6H3/t22-/m0/s1
  • Key:MVKIWCDXKCUDEH-QFIPXVFZSA-N

Fedotozine (INN; JO 1196 for the (-) tartrate salt) is an opioid drug which acts as a peripherally specific selective κ1-opioid receptor agonist with preference for the κ1A subtype.[1] It was under investigation for the treatment of gastrointestinal conditions like irritable bowel syndrome and functional dyspepsia and made it to phase III clinical trials,[1][2][3] but ultimately development was discontinued and it was never marketed.

  1. ^ a b Delvaux M (January 2001). "Pharmacology and clinical experience with fedotozine". Expert Opinion on Investigational Drugs. 10 (1): 97–110. doi:10.1517/13543784.10.1.97. PMID 11116283. S2CID 41361900.
  2. ^ Barber A, Gottschlich R (October 1997). "Novel developments with selective, non-peptidic kappa-opioid receptor agonists". Expert Opinion on Investigational Drugs. 6 (10): 1351–68. doi:10.1517/13543784.6.10.1351. PMID 15989506.
  3. ^ Lembo A (2006). "Peripheral opioids for functional GI disease: a reappraisal". Digestive Diseases. 24 (1–2): 91–8. doi:10.1159/000090312. PMID 16699267. S2CID 29627937.